Meloxicam, a quite new cyclo-oxygenase inhibitor, belongs to the enolic acids class of NSAIDs. It is approved by FDA for the long-term treatment of osteoarthritis, rheumatoid arthritis, ankyloising spondolytis and so forth. It has a poor aqueous solubility [1] and therefore, on oral administration, it remains as unionized lipophilic form in the highly acidic stomach region. These conditions support the migration into the surface epithelial cells where it is dissociated into an ionized form that traps hydrogen ions, consequently producing highly critical local concentration, which lead to irritation in the stomach wall, stomach pain, rupture of gastric mucosa, gastric bleeding and ulceration [2,3], this risk may become much higher for people who are older in age [4], have poor health, or consume a large quantity of alcohol [5]. Moreover, the poor solubility and slow dissolution rate of the lipophilic drugs in the gastrointestinal fluid, besides posing difficulties in the manufacture of pharmaceutical preparations such as liquid orals, may also give rise to fluctuating oral bioavailability and poor therapeutic response of the drug [6].